

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

1 SJCRH	
Reagent:	± vv1002
Catalog Number:	2997
Lot Number:	
Provided:	0.5 ml cell-free virus (5 x 10^6 pfu). Propagate on mammalian cell monolayers, using TK-cells in the presence of BUDR.
Description:	A pSC11-based plasmid encoding a truncated IIIB-derived (B10) envelope gene was modified to remove the b-gal-coding fragment. The BH10 V1-V3 region was replaced with the corresponding sequence from a Memphis HIV-1 isolate (the remaining HIV-1 sequences derived from BH10). The substituted vector was recombined with vaccinia virus (WRwt) by disruption of the TK gene. A live virus was propagated on TK-143B cells in the presence of BUdR.
Special Characteristics:	Virus is cytophathic. Virus expresses the HIV-1 envelope protein as a truncated product inclusive of external gp120 and gp41. The V1/V2 region has been partially sequenced (SWGSVDKGEI KNCSFNITTG IRDKVQKGYA YFYIPDIDQI NDNNNDNTSY RLINCNT). Expression is driven by the P7.5 early/late promoter. The virus may be used for the elicitation and analysis of HIV-1 Env-specific immunity or the preparation of CTL target cells. Sterility: Negative for bacteria and mycoplasma.
Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Julia Hurwitz.
References:	Slobod KS, Rencher SD, Farmer A, Smith FS, Hurwitz JL. HIV type 1 envelope sequence diversity in an inner city community. <i>AIDS Res Hum Retroviruses</i> 10 :873-875, 1994. Ryan KW, Ownes RJ, Hurwitz JL. Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. In: <i>Immunology Methods Manual</i> , I Lefkovits (Ed), Academic Press 1995. Hallenberger S, Tucker SP, Owens RJ, Bernstein HB, Compans RW. Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. <i>Virology</i> 193 :510-514, 1993.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vv1002 from Dr. Julia Hurwitz." Please include the references cited above in any publications.

The US Government has submitted a patent application on the parent plasmid pSC11.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: <u>hus@mail.nih.gov</u>, Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated: June 24, 2013

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.